Study identifier:1839IL/0105
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An open label non comparative phase II trial of ZD1839 (Iressa) in combination with docetaxel (TAXOTERE) in patients with advanced or metastatic non small cell lung cancer failing or unsuitable for platinum based chemotherapy
lung cancer
Phase 2
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|